Profile data is unavailable for this security.
About the company
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
- Revenue in CAD (TTM)6.13m
- Net income in CAD-17.10m
- Incorporated1990
- Employees21.00
- LocationCOSCIENS Biopharma IncC/O Norton Rose Fulbright Canada Llp222 Bay Street, Suite 3000,PO Box 53TORONTO M5K 1E7CanadaCAN
- Phone+1 (418) 652-8525
- Fax+1 (418) 948-9191
- Websitehttps://www.zentaris.com/
Mergers & acquisitions
| Acquired company | CSCI:TOR since announced | Transaction value |
|---|---|---|
| Ceapro Inc | 91.72% | 15.86m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicure Inc | 20.93m | -2.63m | 10.54m | 25.00 | -- | 0.5394 | -- | 0.5036 | -0.2529 | -0.2529 | 1.94 | 1.87 | 0.7288 | 2.28 | 4.38 | 837,280.00 | -9.16 | -13.42 | -12.73 | -18.28 | 61.41 | 61.87 | -12.56 | -27.38 | 1.42 | -- | 0.0202 | -- | -5.94 | -5.71 | -167.55 | -- | -28.82 | -- |
| Numinus Wellness Inc | 20.10m | -24.36m | 11.28m | -- | -- | 2.42 | -- | 0.5612 | -0.0906 | -0.0946 | 0.0752 | 0.0145 | 0.8572 | -- | 11.72 | -- | -103.89 | -77.31 | -129.39 | -84.20 | 30.80 | -- | -121.19 | -323.32 | -- | -13.08 | 0.6044 | -- | 256.95 | -- | 32.59 | -- | -- | -- |
| Telo Genomics Corp | 0.00 | -2.97m | 11.56m | 8.00 | -- | 18.44 | -- | -- | -0.0434 | -0.0434 | 0.00 | 0.0084 | 0.00 | -- | -- | 0.00 | -323.36 | -85.03 | -407.98 | -113.86 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.66 | -- | 24.41 | -- |
| Resverlogix Corp | 0.00 | -14.57m | 17.98m | 18.00 | -- | -- | -- | -- | -0.0559 | -0.0559 | 0.00 | -0.3805 | 0.00 | -- | -- | 0.00 | -138.80 | -- | -- | -- | -- | -- | -- | -- | 0.0459 | -0.8227 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
| Sirona Biochem Corp | -12.09k | -2.31m | 18.12m | -- | -- | -- | -- | -- | -0.0091 | -0.0091 | -0.00005 | -0.012 | -0.0114 | -- | 0.5203 | -- | -218.11 | -173.09 | -- | -383.49 | -- | -- | -- | -1,405.28 | -- | -8.11 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
| COSCIENS Biopharma Inc | 6.13m | -17.10m | 20.55m | 21.00 | -- | 0.4783 | -- | 3.35 | -12.69 | -12.69 | 3.62 | 11.62 | 0.0936 | 1.74 | 6.35 | -- | -26.11 | -26.24 | -30.53 | -30.34 | 39.42 | 83.68 | -278.95 | -300.31 | 3.05 | -- | 0.0604 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
| Briacell Therapeutics Corp | 0.00 | -8.14m | 27.02m | 11.00 | -- | -- | -- | -- | -0.531 | -0.531 | 0.00 | -0.5065 | 0.00 | -- | -- | 0.00 | -33.97 | -59.37 | -43.50 | -63.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.35 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Goodwood, Inc.as of 05 Jun 2024 | 44.67k | 1.46% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 4.04k | 0.13% |
| Citadel Securities LLCas of 31 Mar 2024 | 3.96k | 0.13% |
| BMO Asset Management Corp.as of 31 Mar 2024 | 2.77k | 0.09% |
| Edmond de Rothschild (Suisse) SA (Investment Management)as of 31 Mar 2024 | 1.00k | 0.03% |
| Geode Capital Management LLCas of 30 Jun 2024 | 914.00 | 0.03% |
| National Bank Financial, Inc.as of 30 Jun 2024 | 844.00 | 0.03% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 181.00 | 0.01% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 116.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 50.00 | 0.00% |
